Articles Tagged With:
-
The Big Chill: IRB Critic Says Changes Fall Short
IRB Advisor asked Zachary M. Schrag, PhD, to weigh in on his past concerns in light of the revised changes to the Common Rule.
-
Social Research Exemptions and Common Rule: It’s Complicated
Social scientists, behavioral researchers, and their respective IRBs find themselves in the midst of a somewhat complicated debate about how and to what extent the Common Rule changes affect or exempt oversight of their endeavors by the Office of Human Research Protections.
-
Clinical Briefs
In this section: Effects of weight gain on the cardiovascular system; comparing sleep apnea treatments; and rhabdomyolysis brought on by exercise.
-
Edaravone Injection (Radicava)
The FDA has approved edaravone, the first new treatment for amyotrophic lateral sclerosis since the approval of riluzole more than 20 years ago.
-
Guillain-Barré Syndrome and Hepatitis E
Hepatitis E is the most common form of viral hepatitis worldwide and often is asymptomatic, but it is commonly associated with Guillain-Barré syndrome and Guillain-Barré variants.
-
Treatment of Chronic Fatigue/Myalgic Encephalitis Syndrome
Blockade of IL-1 activity with anakinra failed to reduce fatigue in patients with chronic fatigue syndrome.
-
Very Low-carbohydrate Ketogenic Diet May Reverse Type 2 Diabetes
A very low-carbohydrate ketogenic diet demonstrated superiority to the plate method diet recommended by the American Diabetes Association for controlling and even reversing type 2 diabetes.
-
No Single Solution to Prevent Medication Nonadherence
Simple, low-cost reminder pill bottles did not lead to more improvement in medication adherence in patients with documented poor adherence.
-
What Are Your Patients ‘Hearing’ About Menopausal Hormonal Therapy?
Data from the prospective Nurses’ Health Study demonstrate a weak association between menopause onset after age 50 years and use of hormone therapy and hearing loss. The most likely explanation is “noise.”
-
Genital HPV in Men: How Common Is It?
In this U.S. cross-sectional survey, the prevalence of genital human papillomavirus (HPV) infection in adult men was 45%, of which 25% were high-risk subtypes. The overall rate of HPV vaccination among those who were eligible was 11%.